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| INTRODUC TI ON
Von Willebrand factor (VWF) is a large multimeric protein that plays a central role in vascular homeostasis. VWF is synthesized by endothelial cells (ECs) and megakaryocytes and secreted VWF mediates adhesion of platelets to sites of vascular damage and acts as a carrier for coagulation factor VIII. 1 The importance of synthesis and secretion of VWF is highlighted by the bleeding disorder von
Willebrand disease (VWD), which is caused by mutations in the VWF gene that lead to either qualitative or (full or partial) quantitative deficiencies in VWF. 2 Elevated levels of VWF, on the other hand, have been associated with increased risk of thrombosis. 3 Following its synthesis in ECs, VWF is stored in rod-shaped storage organelles, called Weibel-Palade bodies (WPBs), where it is stored together with a wide variety of inflammatory and angiogenic mediators. [4] [5] [6] VWF is the driving force behind the formation of its own storage organelle, illustrated by the lack of WPBs in ECs from a patient with severe VWD type 3 7 or from VWF null animal models [8] [9] [10] and the formation of pseudo-WPBs upon heterologous expression of VWF in other cell types. [11] [12] [13] Upon endothelial triggering, that is, after vascular damage, WPBs undergo exocytosis and deliver their cargo to the cell surface or into the vascular lumen, leading to the formation of long VWF strings to which platelets and also leukocytes and erythrocytes can adhere. [14] [15] [16] [17] [18] Absence of WPBs not only compromises the hemostatic response of the endothelium but also has consequences for other secretory cargo that relies on WPBs for proper delivery to and across the plasma membrane. Trafficking of several inflammatory mediators, including P-selectin, CD63, and chemokines such as interleukin (IL)-6 and IL-8, is likely to depend on VWF synthesis and WPB formation. 19 This is underscored by impaired leukocyte rolling and neutrophil infiltration in wounds in VWF −/− mice, resulting from defective translocation of P-selectin and/or CD63. 8, [20] [21] [22] In addition, storage and secretion of another WPB cargo protein, the proangiogenic mediator angiopoietin (Ang)-2 [23] [24] [25] is also disturbed when ECs are depleted of VWF. 26 Continuous release of Ang-2 as a consequence of the unavailability of its default storage compartment has been proposed as one of the underlying mechanisms behind angiodysplasia, a clinical complication of VWD that is characterized by recurrent bleeding in the gastrointestinal tract and is associated with vascular malformations of the gut. 27, 28 However, studies into angiogenic properties of blood outgrowth endothelial cells (BOECs) derived from patients with VWD, which can be regarded as endothelial models of VWD, have failed to unequivocally support this model. 7, 26, 29, 30 Variation in the genetic background between patients as well as controls may be at the basis of the discrepancy between outcomes in BOECs derived from different individuals. This is further confounded by the broad spectrum of VWD-causing mutations and the residual VWF expression levels that are associated with these mutations. 31 To overcome this, there is a need for targeted genetic strategies for long-term complete ablation of VWF in human primary ECs. Others have previously used the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated protein 9 (Cas9) system to target gene expression in ECs in vitro. 32, 33 In this study, we used CRISPR-Cas9 genetic engineering to knock out VWF expression using guide RNAs that tar- 
Essentials
• Von Willebrand factor (VWF) synthesis is essential for the formation of the Weibel-Palade Bodies (WPBs).
• Patient-derived endothelial cell models of von Willebrand disease and VWF deficiency have shown a high degree of phenotypic heterogeneity.
• We generated VWF knockout endothelial cells (ECs) using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated protein 9 gene editing on cord blood outgrowth ECs (cbBOECs).
• WPB-associated proteins show alternative localization in the absence of VWF, and angiopoietin (Ang)-2 colocalizes with the receptor Tie-2.
were selected using a high-throughput screen for loss of VWF 
| METHODS

| Antibodies and reagents
Antibodies used in this study are listed in Table S1 .
| Isolation of cbBOECs and cell culture
Cord blood was collected from umbilical veins within 48 hours after delivery and was processed for BOEC isolation essentially as described before. 35 
| Lentiviral CRISPR-Cas9 targeting constructs
Guide RNA (gRNA) sequences targeting the first exon of VWF were designed using the MIT CRISPR design tool (http://crispr.mit.edu) 37 and the BROAD Institute single guide RNA (sgRNA) designer (http:// www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design) 38 by submitting the DNA sequence of VWF exon 1 flanked by 100 bp up-and downstream (chromosome 12, 6123020-6123259 positive strand; Figure 1 ). gRNA sequences were selected that have a high predicted efficiency (BROAD Institute score) and a high inverted offtarget score (MIT CRISPR design tool). 37, 38 gRNAs used in this study 
| Generation of CRISPR-edited VWF −/− cbBOECs
| Secretion assay
ECs were seeded in gelatin-coated 6-well plates and cultured at full confluency for 4 to 5 days. Twenty-four hours before the secretion assay, media were replaced for fresh EGM-18 supplemented with 10 ng/mL of IL-1β (I9401, Sigma-Aldrich, St Louis, MO) or vehicle.
Twenty-four-hour conditioned media were harvested, cells were pretreated for 15 minutes with serum-free M199 medium (Gibco 22340, ThermoFisher) supplemented with 0.2% (w/v) bovine serum albumin (BSA; Serva, Heidelberg, Germany) and were stimulated with 100 μmol/L of histamine or vehicle for 30 minutes as described previously. 41 Releasates were collected, and stimulated and unstimulated ECs were lysed in M199 with 0.2% BSA and 1% Triton X-100 (Sigma-Aldrich). Protein secretion and intracellular content were determined using the DuoSet ELISA kit for Ang-2 (DY623; R&D Systems, Minneapolis, MN), and the Pelikine compact kit for IL-6 and IL-8 (M1916 and M1918, respectively; Sanquin, Amsterdam, The Netherlands). Assays were performed according to manufacturer's protocol.
| Statistical analysis
Statistical analyses were performed in Prism 8. Step 1 -Design guide RNAs (gRNAs) against the first exon of VWF
Step 2 -Clone gRNAs into LenitiCRISPR vector
Step 3 -Lentivirus production in HEK293T
Step 5 -Single-cell sorting by follow cytometry VWF ELISA lysate WB gDNA sequencing
Step 6 -VWF ELISA of conditioned medium to identify biallelic VWF knockout clones
Step 7 -Expand biallelic VWF knockout clones
Step 8 -Confirm biallelic VWF knockout by WB and sequencing
Step 4 -Transduction of cbBOEC and selection with puromycin Significance values are specified in figure legends.
| Mass spectrometry
Cells were lysed, processed into tryptic peptides and analyzed by mass spectrometry using an Orbitrap Fusion Tribid mass spectrometer (ThermoFisher). Data were processed using the Maxquant computational platform essentially as described. 42 The .raw MS files and search/identification files obtained with MaxQuant were deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD013857. A more detailed description of the mass spectrometry sample acquisition and data analysis is provided in Data S1.
| RESULTS
| Generation of CRISPR/Cas9 mediated VWF knockout cord blood outgrowth endothelial cells
Two Table S2 ). Other low-frequency variants that were picked up by NGS were most probably the result of sequence read errors (Table S2 ). These results show that the loss of VWF expression is the direct result of targeted mutations brought about by CRISPR/Cas9-induced double strand breaks in the first exon.
We next sought to confirm that our CRISPR-edited BOEC clones had retained their EC characteristics. CTRL and VWF −/− BOEC clones all formed confluent monolayers with a typical cobblestone morphology (not shown). All clones expressed endothelial markers VE-cadherin (CD144; Figure 3 ) and platelet EC adhesion molecule-1 (CD31; Figure S2 ) at cell-cell junctions with no obvious differences between VWF −/− and CTRL clones. Immunostainings using a selection of monoclonal and polyclonal antibodies directed against VWF showed normal distribution and morphology of WPBs in CTRL clones A and B, whereas VWF −/− clones were completely devoid of WPBs or remaining VWF immunoreactivity ( Figure 3 ). Finally, all clones were able to form networks in a Matrigel-based morphogenesis assay in the presence of vascular endothelial growth factor (VEGF; Figure S3A ) and maintained LDL uptake capacity ( Figure S3B ). These results show that we have generated VWF null BOEC clones that have otherwise preserved their normal endothelial properties.
| Whole-proteome analysis of VWFdeficient BOEC
To determine whether, apart from morphologic or functional differences, loss of VWF induces changes in the overall protein expression F I G U R E 1 Schematic overview of the CRISPR clone generation workflow. Guide RNAs (gRNAs) were designed to target exon 1 of the VWF gene (Step 1) and cloned into a LentiCRISPR V2 vector (Step 2). HEK293T cells were transfected with a vector containing a VWF targeting gRNA (gRNA-1 or gRNA-2) or the empty LentiCRISPR vector as a control (CTRL) (Step2). Lentivirus was produced in endothelialcell growth medium 18, and medium was transferred to cord blood outgrowth endothelial cells (cbBOECs) from a single donor for transduction either directly or after combining medium containing 2 gRNAs, sometimes combining virus containing 2 different gRNAs for increased targeting efficiency (Step 4). Transduced cells were selected by puromycin and single-cell sorted using vascular endothelial (VE)-cadherin as an endothelial cell surface marker (Step 5). Medium of single-cell clones was collected for an ELISA-mediated high-throughput screen for von Willebrand factor (VWF) deficient clones. Putative knockout clones were expanded to multiple larger culture surfaces for western blot (WB) and sequencing analysis to confirm biallelic VWF knockout (Step 8), after which they were cryopreserved or used for functional assays profile of ECs. We compared expression profiles of 2 independent CTRL and 2 independent VWF −/− BOEC clones using label-free mass spectrometry-based protein quantification. From this, we quantified the abundance of 4371 proteins, of which only a limited number (17) was significantly up-or downregulated in VWF −/− BOECs ( Figure 4A ; a separate, side-by-side comparison of the individual clones is shown in Figure S4 ). As expected, the largest difference was seen for VWF, further confirming that we knocked out its expression in our CRISPRengineered BOECs. Proteins with statistically significant changes in expression are shown in Figure 4B , which includes among others 9  10  11  12  13  14  15  16  17  18  19  20  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  1  2  3  4  5  6  7  8  9  10  11  12  13  14 were represented in our data set, remained unchanged ( Figure 4C ).
This suggests that these proteins are still present, although they may display alternative localizations in the absence of WPBs. The expression profiles of a select array of WPB and endothelial markers 43 presented no differences between CTRL and VWF −/− clones ( Figure 4C ), establishing that apart from lacking VWF, these cells have retained their endothelial characteristics.
| Alternative routing of Weibel-Palade body cargo proteins
As genetic ablation of VWF also leads to the absence of WPBs, we hypothesized that proteins that are normally stored in or associated with these granules would now be subject to alternative trafficking pathways, resulting in a change in cellular expression. To test this, we investigated the localization of a number of WPB (cargo) proteins that are involved in inflammation, angiogenesis, and WPB trafficking using immunocytochemistry. In VWF-deficient ECs, 2 chemokines that are normally stored in WPBs upon upregulation with IL-1β, IL-6, and IL-8, were now primarily found in small punctate structures, which may represent small constitutive secretory vesicles and a ribbon-like pattern consistent with their accumulation in the Golgi ( Figure 5A,C) . [44] [45] [46] [47] Because only a small portion of IL-6 and IL-8 is stored inside WPBs, 19, 46 we addressed whether loss of WPBs has an effect on functional release of these cytokines. Therefore, we stimulated CTRL and VWF −/− for 24 hours with IL-1β and assayed their unstimulated and histamine-evoked release by ELISA ( Figure 5B and D) .
Overall, no significant differences were found in terms of intracellular content or absolute release between control and knockout ECs.
In VWF −/− , B cytokine release relative to intracellular content appears to be increased, but not in VWF −/− A. However, the production The angiogenesis mediator Ang-2 is another protein that, like IL-8, is thought to be coackaged in the WPB during its formation at the trans-Golgi network (TGN), possibly through noncovalent interaction with VWF. 48 Also for Ang-2, we observed a punctate pattern in the absence of WPBs, as well as an overall decrease in Ang-2 signal ( Figure 6 ). However, whereas the punctae of IL-6 and IL-8 were diffusely distributed throughout the cell, Ang-2 shows enrichment at cell-cell junctions ( Figure 6 see also Figure S5 ). It has been suggested previously that altered angiogenic properties of ECs lacking VWF may be caused by increased constitutive release of Ang-2, which would then lead to autocrine/paracrine regulation of Tie-2 signaling. 28 In line with this, we observed that 
| DISCUSSION
In this study, we generated stable VWF knockout ECs using CRISPR/ Cas9 gene editing, resulting in ECs entirely devoid of WPBs. To our knowledge, this is the first study to report the ablation of an entire organelle using CRISPR/Cas9. A number of studies have previously employed CRISPR/Cas9 to knock out expression of targets in ECs.
In most of those studies, no single-cell selection and clonal expansion was performed, but a bulk population was used in which a proportion of the cells may still express the targeted protein. 33, 53 Single-cell cloning is needed to arrive at genetically homogeneous populations of ECs that have lost expression of the target gene, but the extensive passaging involved places high demands on the proliferative capacity of modified endothelial cells. Our approach was similar to a methodological study in which clonal endothelial lines were generated after single-cell sorting of CRISPR-edited cbBOECs, 32 proteins of interest, an extra expansion step would be required for immediate clone selection through western blotting, as we have previously described. 52 To ensure that phenotypic differences that we observed are not the result of (1) and/or IL-8 levels in VWD patients, but based on our in vitro observations, the likelihood of these deviating significantly from healthy subjects is limited, given that most EC-derived IL-6 or IL-8 is not released via the WPBs.
WPBs also facilitate the long-term storage of the angiogenesis mediator Ang-2 and ensure its on-demand availability during proangiogenic conditions, for instance, in response to triggering of WPB release by VEGF. 28 Previous studies have also shown altered levels of continuous Ang-2 release from ECs from patients with VWD or after small interfering RNA-mediated VWF knockdown, which has been suggested to be in part the underlying cause of altered angiogenic properties of VWD patient-derived BOECs and the angiodysplasia that is observed in some patients with VWD. 26, 30 This hypothesis is supported by the current finding that when Ang-2 cannot be stored in the WPBs, it no longer appears to localize to storage vesicles but is released constitutively (Figure 6 ). However, a recent study on circulating levels of angiogenic mediators in patients with moderate and severe VWD did not find (statistically significant) differences in circulating levels of Ang-2 in patients with normal and impaired VWF synthesis. 63 Secreted Ang-2 takes part in the complex regulation of angiogenesis through the interaction with a number of EC surface receptor proteins, including Tie-2 and several integrins. 
